AstraZeneca

AstraZeneca and Lilly to collaborate on immuno-oncology combination clinical trial in solid tumours

29 Maj 2015 08:02

AstraZeneca and Eli Lilly and Company (Lilly) today announced that they have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ramucirumab (CYRAMZA®), Lilly’s VEGF Receptor 2 antiangiogenic cancer medicine. The planned study will assess the combination as

AstraZeneca provides update on brodalumab development programme

22 Maj 2015 22:29

Amgen today announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.

AstraZeneca investerar i ny anläggning i Södertälje för tillverkning av biologiska läkemedel

18 Maj 2015 10:10

AstraZeneca meddelar i dag sina planer på att investera cirka 285 miljoner USD i en ny högteknologisk anläggning för tillverkning av biologiska läkemedel i Gärtuna utanför Södertälje. Den nya anläggningen kommer fokusera på fyllning och packning av proteinläkemedel. Det förväntas att den nya enheten kommer att producera läkemedel till kliniska prövningsprogram för AstraZeneca och Medimmune, koncer

AstraZeneca to update on progress with Immuno-Oncology pipeline and combination treatments at ASCO 2015

13 Maj 2015 23:05

AstraZeneca and MedImmune, the Company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May-2 June 2015

AstraZeneca and Abbott to develop companion diagnostic tests for tralokinumab in severe asthma

13 Maj 2015 08:02

AstraZeneca today announced that it has entered an agreement with Abbott, a global healthcare company, to develop companion diagnostic tests to identify patients with severe asthma who are most likely to benefit from the investigational biological therapy, tralokinumab.

AstraZeneca and Montreal Heart Institute to screen 80,000 samples for cardiovascular and diabetes genetic traits

13 Maj 2015 08:02

AstraZeneca today announced a collaboration with the Montreal Heart Institute (MHI) in Quebec, Canada, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes.

Svenska Lungcancerstudiegruppen (SLUSG) delar ut stipendium

8 Maj 2015 11:17

Idag tilldelas Leg.läk. Professor Rolf Lewensohn, verksam vid Karolinska Institutet och Överläkare vid Onkologiska kliniken Karolinska Universitetssjukhuset i Stockholm, SLUSG-stipendiet 2015.

US FDA grants Priority Review for potential new indication for BRILINTA

29 April 2015 08:02

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for BRILINTA® (ticagrelor) tablets for patients with a history of heart attack. The sNDA is based on the results of the PEGASUS-TIMI 54 study, a large-scale outcomes trial in more than 21,000 patients that investigated ticagrelor tablets plu

Positive phase III results for two antibiotics, ZINFORO™ and investigational ceftazidime-avibactam, presented at leading Infectious Diseases Conference

27 April 2015 11:24

Encouraging new data of relevance to Global public health crisis, presented at 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

AstraZeneca PLC: Delårsrapport för första kvartalet 2015 - sammanfattning. Bifogat finns den fullständiga rapporten

24 April 2015 08:06

Det finansiella resultatet för kvartal 1 2015 ger stöd åt upprepad helårsprognos för 2015.

oTotala intäkter (definierat som produktförsäljning och intäkter från externa samarbeten1) ökade med 1% i fasta valutakurser 2 (CER) till 6 057 MUSD (Q1 2014: 6 460 MUSD)
oVinst per aktie för kärnverksamheten (Core EPS) minskade med 3% till1,08 USD i takt med att vi fortsätter att investera i att

AstraZeneca enters strategic immuno-oncology collaboration with Celgene Corporation to develop PD-L1 inhibitor programme for patients with serious blood cancers

24 April 2015 07:05

AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into an exclusive collaboration agreement with Celgene Corporation, a global leader in haematological cancers, for the development and commercialisation of MEDI4736

AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology

24 April 2015 07:00

AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into a collaboration to accelerate and broaden the development of Innate Pharma SA’s proprietary anti-NKG2A antibody

Nyhetsarkiv